Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

NovoCure Limited - Ordinary Shares (NQ: NVCR )

30.80 +0.40 (+1.32%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NovoCure Limited - Ordinary Shares

< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
Unusually Heavy Friday
Today is a heavy news day, which is unusual for a Friday. We start with the largest company's lamentable report, follow with another confusing result, then a hopeful drug company report, and finish... 
Via Talk Markets
Stock Market Rally Navigates Earnings From Apple, Tesla, Google, Facebook, Microsoft, Amazon
The stock market rally navigated earnings from Apple, Tesla and the other "big six" market cap companies. Many breakouts, but not all succeeded. 
Via Investor's Business Daily
Is Novocure Stock Overvalued?
Did the market overreact to the company's good news? 
Via The Motley Fool
Recap: NovoCure Q1 Earnings
Shares of NovoCure (NASDAQ:NVCR) fell 2.7% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share were down 200.00% year over... 
Via Benzinga
Earnings Scheduled For April 29, 2021
Companies Reporting Before The Bell • OSI Systems (NASDAQ:OSIS) is estimated to report quarterly earnings at $1.33 per share on revenue of $290.51 million. •... 
Via Benzinga
Another Heavy News Day
For whatever it is worth, markets seem keen on the proposed measures, boosted by a nicely lower level of new unemployment insurance claims last week. 
Via Talk Markets
NovoCure (NVCR) Q1 2021 Earnings Call Transcript
NVCR earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Novocure Reports Surprise Loss As Revenue Falls Short
Novocure reported a surprise loss as the cancer-fighting medtech missed on revenue. NVCR stock fell. 
Via Investor's Business Daily
Novocure Reports First Quarter 2021 Financial Results and Provides Company Update
From Novocure
Via Business Wire
The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 28) Axonics, Inc. (NASDAQ:... 
Via Benzinga
London Cancel
Brazilian Cosan is up 0.43% despite desperate Covid-19 outbreaks along the Amazon. 
Via Talk Markets
Exposures COVID-19
The Daily Biotech Pulse: FDA Rejection For Protalix, Amgen Q1 Trail Estimates, Pfizer Goes Shopping
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 27) Aldeyra Therapeutics, Inc... 
Via Benzinga
Exposures Product Safety
Earth Day
Once again the exchanges are unsure if they want to go up or down. 
Via Talk Markets
The Daily Biotech Pulse: Lilly, Novartis Trail Q1 Estimates, Exec Departure At Applied Genetics, Patent Award For Scholar Rock, Aldeyra Data Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 26) 10x Genomics, Inc. (NASDAQ... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Novocure Announces FDA IDE Approval and Steering Committee for KEYNOTE-B36 Trial Evaluating Tumor Treating Fields Together with Pembrolizumab in Non-Small Cell Lung Cancer
From Novocure
Via Business Wire
The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx
Biopharma stocks came back from the weakness seen in the first two sessions to close the week ended April 23 higher. Johnson & Johnson (NYSE: JNJ) and Roche Holding AG (OTC:... 
Via Benzinga
Exposures Product Safety
Cancer Therapy Novocure Stock Still On A High As It Clears Technical Benchmark
Cancer therapy Novocure stock had its Relative Strength (RS) Rating upgraded from 90 to 93 Wednesday. It's also an IBD 50 member. 
Via Investor's Business Daily
Is Novocure a Buy?
Once a stock goes up 50% in a single day, it can be hard to keep the momentum going. 
Via The Motley Fool
Why Investors Are So Excited About Novocure
The company's Tumor Treating Fields therapy looks very promising in treating lung cancer. 
Via The Motley Fool
Currency Manipulation
London's FTSE 100 index today rose over 7000 for the first time in 14 months. It hit 7019.53. 
Via Talk Markets
This Stock Just Popped 40%. Here's Why It Can Continue to Crush the Market
Novocure has provided stellar returns over the last five years, now up 17 times. Recent positive news may keep its stock going up. 
Via The Motley Fool
Stock Market Rally Keeps Rising As Treasury Yields Fall Despite Strong Earnings, Economic Data; Goldman, Nvidia, Coinbase In Focus
Tumbling yields and strong economic data fueled stocks. Goldman earnings, Nvidia news and the Coinbase IPO were in focus. 
Via Investor's Business Daily
Topics Initial Public Offering Stocks
Exposures Securities Market US Equities
Happy News Day
The stock markets are in clover because March retail sales hit 9.8% according to the Department of Commerce. 
Via Talk Markets
Stunning Market Debut
Wednesday brought a zip into the accounts of many financial stocks thanks to a boom result from Goldman Sachs GS, which boosted its competitors' prices. 
Via Talk Markets
Cancer Therapy Novocure Stock Flashes Renewed Technical Strength
Novocure stock saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, with an increase from 67 to 92. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Akumin (NASDAQ:AKU) shares increased by 13.54% to $3.52 during Wednesday's pre-market session. The market value of their outstanding shares is at $247.0... 
Via Benzinga
10 Biggest Price Target Changes For Wednesday
JP Morgan raised Southwest Airlines Co. (NYSE: LUV) price target from $44 to $66. Southwest Airlines shares rose 1% to $63.79 in pre-market trading. Keybanc boosted Public... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 14, 2021
Upgrades For Cardlytics Inc (NASDAQ:CDLX), Craig-Hallum upgraded the previous rating of Hold to Buy. For the fourth quarter, Cardlytics had an EPS of $0.05, compared to... 
Via Benzinga
The Daily Biotech Pulse: Novavax CFO Departs, Zai Lab Inks Cancer Drug Collaboration, FDA Nod For Gilead
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 13) Bio-Techne Corporation (... 
Via Benzinga
Exposures Product Safety
50 Biggest Movers From Yesterday
Gainers Mackinac Financial Corporation (NASDAQ: MFNC) shares surged 60.7% to close at $21.16 on Tuesday after the company, and Nicolet Bankshares, jointly announced the execution... 
Via Benzinga
< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.